Form 8.3 - Horizon Therapeutics plc

LONDON--(BUSINESS WIRE)-- 

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)	Millennium International Management LP
Company dealt in	Horizon Therapeutics plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	IE00BQPVQZ61
Date of dealing	20^th June 2023

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	4,189,559 (1.831%)		-
(2) Derivatives (other than options)	511,000 (0.223%)		511,000 (0.223%)
(3) Options and agreements to purchase/sell	1,535,600 (0.671%)		2,008,700 (0.878%)
Total	6,236,159 (2.726%)		2,519,700 (1.101%)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (USD) (Note 5)
Sale	295	101.43
Sale	400	101.18
Purchase	195	101.15
Sale	900	101.15
Sale	900	101.14
Sale	100	101.06
Sale	1,300	101.25
Sale	1,000	101.09
Sale	250	101.10
Sale	1,400	101.19
Sale	4,904	101.38
Sale	2,500	101.39
Sale	1,199	101.46
Sale	100	101.03
Sale	2,100	101.13
Sale	2,400	101.17
Sale	800	101.37
Sale	141	101.41
Sale	100	101.01
Sale	200	101.27
Sale	4,002	101.40
Sale	100	101.29
Sale	104	101.36
Sale	7,967	101.43
Purchase	93	101.18
Purchase	138	101.15
Purchase	15	101.16
Purchase	22	101.14
Purchase	42	101.11
Purchase	34	101.08
Purchase	6	101.25
Purchase	420	101.09
Purchase	30	101.22
Purchase	441	101.10
Purchase	899	101.46
Purchase	10	101.03
Purchase	120	101.07
Purchase	102	101.13
Purchase	22	101.17
Purchase	976	101.42
Purchase	2	101.21
Purchase	39	101.15
Purchase	483	101.12
Purchase	72	101.14
Purchase	49	101.11
Purchase	400	101.08
Purchase	14	101.22
Purchase	577	101.10
Purchase	162	101.07
Purchase	13	101.13
Purchase	14	101.45
Purchase	4,002	101.40
Sale	273	101.43
Purchase	100	101.63
Purchase	500	101.15
Purchase	802	101.12
Purchase	100	101.14
Purchase	246	101.06
Purchase	2,538	101.11
Purchase	353	101.08
Purchase	4,228	101.09
Purchase	2,526	101.10
Sale	293	101.38
Purchase	150	101.39
Sale	6	101.46
Purchase	200	101.07
Purchase	100	101.61
Purchase	1,312	101.00
Purchase	300	101.13
Sale	976	101.42
Sale	384	101.32
Purchase	100	101.05
Sale	97	101.47
Purchase	200	101.35
Sale	1,008	101.40
Sale	195	101.29
Purchase	286	101.43
Purchase	2	101.39
Purchase	1	101.46
Purchase	7	101.42
Purchase	1	101.48
Purchase	1	101.50
Purchase	2	101.49

(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD

Nature of transaction (Note 6)

Number of relevant securities (Note 7)

Price per unit (USD) (Note 5)

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price (USD)	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)
Call Option	Purchasing	7,800	105.00	American	6/23/2023

(ii) Exercising

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)

Details

Price per unit (if applicable) (Note 5)

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None.

Is a Supplemental Form 8 attached? (Note 9) YES

Date of disclosure	21^st June 2023
Contact name	Stephen Glasper
Telephone number	[phone]
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

Ap32

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND

RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING

OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND

RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1. KEY INFORMATION

Full name of person making disclosure:	Millennium International Management LP
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:	Horizon Therapeutics plc

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of relevant security	Product description e.g. call option	Written or purchased	Number of securities to which option or derivative relates	Exercise price per unit (USD)	Type e.g. American, European etc.	Expiry date
IE00BQPVQZ61	Put Option	Purchased	300	80.00	American	1/17/2025
IE00BQPVQZ61	Put Option	Purchased	100,300	90.00	American	1/19/2024
IE00BQPVQZ61	Call Option	Purchased	1,200	110.00	American	8/18/2023
IE00BQPVQZ61	Call Option	Written	201,200	115.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Written	50,000	80.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	29,000	80.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	10,900	105.00	American	7/21/2023
IE00BQPVQZ61	Call Option	Written	300	110.00	American	7/21/2023
IE00BQPVQZ61	Put Option	Written	300	110.00	American	7/21/2023
IE00BQPVQZ61	Put Option	Written	400	110.00	American	8/18/2023
IE00BQPVQZ61	Call Option	Written	400	110.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	250,000	85.00	American	1/19/2024
IE00BQPVQZ61	Put Option	Purchased	50,000	90.00	American	7/21/2023
IE00BQPVQZ61	Call Option	Written	150,000	100.00	American	7/21/2023
IE00BQPVQZ61	Call Option	Purchased	2,500	110.00	American	17/11/2023
IE00BQPVQZ61	Call Option	Purchased	4,500	110.00	American	10/20/2023
IE00BQPVQZ61	Call Option	Purchased	100,000	100.00	American	12/15/2023
IE00BQPVQZ61	Call Option	Written	100,000	110.00	American	12/15/2023
IE00BQPVQZ61	Put Option	Purchased	100,000	85.00	American	8/18/2023
IE00BQPVQZ61	Call Option	Written	2,800	100.00	American	10/20/2023
IE00BQPVQZ61	Call Option	Purchased	2,800	100.00	American	17/11/2023
IE00BQPVQZ61	Put Option	Written	50,000	85.00	American	15/09/2023
IE00BQPVQZ61	Put Option	Purchased	50,000	85.00	American	17/11/2023
IE00BQPVQZ61	Put Option	Purchased	2,600	90.00	American	17/11/2023
IE00BQPVQZ61	Put Option	Purchased	40,900	100.00	American	17/11/2023
IE00BQPVQZ61	Call Option	Purchased	200	100.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	200	100.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	100,000	70.00	American	17/11/2023
IE00BQPVQZ61	Call Option	Purchased	300	100.00	American	15/09/2023
IE00BQPVQZ61	Put Option	Purchased	300	100.00	American	15/09/2023
IE00BQPVQZ61	Put Option	Written	100,000	60.00	American	1/19/2024
IE00BQPVQZ61	Put Option	Written	100,000	100.00	American	7/21/2023
IE00BQPVQZ61	Call Option	Purchased	100,000	110.00	American	15/09/2023
IE00BQPVQZ61	Call Option	Purchased	510,600	110.00	American	1/19/2024
IE00BQPVQZ61	Call Option	Written	510,600	115.00	American	1/19/2024
IE00BQPVQZ61	Put Option	Purchased	308,900	95.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Written	505,000	60.00	American	12/15/2023
IE00BQPVQZ61	Call Option	Purchased	7,800	105.00	American	23/06/2023

3. AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

Ap33

4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS’ AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.